St. Jude Medical (STJ) : Marshwinds Advisory Co reduced its stake in St. Jude Medical by 1.43% during the most recent quarter end. The investment management company now holds a total of 41,365 shares of St. Jude Medical which is valued at $3,233,088 after selling 600 shares in St. Jude Medical , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.St. Jude Medical makes up approximately 1.62% of Marshwinds Advisory Co’s portfolio.
Other Hedge Funds, Including , Private Trust Co Na reduced its stake in STJ by selling 132 shares or 1.43% in the most recent quarter. The Hedge Fund company now holds 9,116 shares of STJ which is valued at $712,507. St. Jude Medical makes up approx 0.18% of Private Trust Co Na’s portfolio.Capstone Asset Management Co boosted its stake in STJ in the latest quarter, The investment management firm added 2,986 additional shares and now holds a total of 83,602 shares of St. Jude Medical which is valued at $6,555,233. St. Jude Medical makes up approx 0.19% of Capstone Asset Management Co’s portfolio.Oregon Public Employees Retirement Fund reduced its stake in STJ by selling 21,062 shares or 41.81% in the most recent quarter. The Hedge Fund company now holds 29,315 shares of STJ which is valued at $2,382,723. St. Jude Medical makes up approx 0.05% of Oregon Public Employees Retirement Fund’s portfolio. Lgt Capital Partners Ltd. sold out all of its stake in STJ during the most recent quarter. The investment firm sold 62,000 shares of STJ which is valued $5,039,360.Boltwood Capital Management boosted its stake in STJ in the latest quarter, The investment management firm added 95 additional shares and now holds a total of 14,360 shares of St. Jude Medical which is valued at $1,153,252. St. Jude Medical makes up approx 0.93% of Boltwood Capital Management’s portfolio.
St. Jude Medical closed down -2.87 points or -3.53% at $78.41 with 1,27,29,347 shares getting traded on Tuesday. Post opening the session at $79.89, the shares hit an intraday low of $78.12 and an intraday high of $80.05 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, St. Jude Medical reported $1.06 EPS for the quarter, based on the information available during the earnings call on Jul 20, 2016. Analyst had a consensus estimate of $1.06. The company had revenue of $1562.00 million for the quarter, compared to analysts expectations of $1552.79 million. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).